Pertuzumab Plus Trastuzumab in Patients With Biliary Tract Cancer With ERBB2/3 Alterations: Results From the Targeted Agent and Profiling Utilization Registry Study.
Timothy L CannonMichael RothePam K MangatElizabeth Garrett-MayerVi K ChiuJimmy HwangNamrata VijayvergiaOlatunji B AleseElie G DibHerbert L DuvivierKelsey A KluteVaibhav SahaiEugene R AhnPablo BedanoDeepti BehlSarah SinclairRamya ThotaWalter J UrbaEddy Shih-Hsin YangGina N GranthamDominique C HinshawAbigail GregorySusan HalabiRichard L SchilskyPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024)
amplification, overexpression, or mutation.